Active	Status	Sponsor type	Region	Phase	Filter
25 Active 9 Inactive 34 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Carella, Angelo Michele
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT	Active, not recruiting	3	249	Europe, Japan, US, RoW	mocravimod	Priothera SAS, Priothera S.A.S.	Adult Acute Myeloid Leukemia	11/25	11/25
Shimoni, Avichai
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT	Active, not recruiting	3	249	Europe, Japan, US, RoW	mocravimod	Priothera SAS, Priothera S.A.S.	Adult Acute Myeloid Leukemia	11/25	11/25
Galieni, Piero
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT	Active, not recruiting	3	249	Europe, Japan, US, RoW	mocravimod	Priothera SAS, Priothera S.A.S.	Adult Acute Myeloid Leukemia	11/25	11/25
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Jul 2024 - Dec 2024 : Data for RRMM	Active, not recruiting	2	177	Europe, Canada, US, RoW	Belantamab mafodotin	GlaxoSmithKline	Multiple Myeloma	08/24	02/25
Saporiti, Giorgia
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT	Active, not recruiting	3	249	Europe, Japan, US, RoW	mocravimod	Priothera SAS, Priothera S.A.S.	Adult Acute Myeloid Leukemia	11/25	11/25
Ishikawa, Takayuki
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT	Active, not recruiting	3	249	Europe, Japan, US, RoW	mocravimod	Priothera SAS, Priothera S.A.S.	Adult Acute Myeloid Leukemia	11/25	11/25
Visiani, Guiseppe
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT	Active, not recruiting	3	249	Europe, Japan, US, RoW	mocravimod	Priothera SAS, Priothera S.A.S.	Adult Acute Myeloid Leukemia	11/25	11/25